Streetbeat News

Revenues

ADTN

Adtran Holdings (NASDAQ:ADTN) has been evaluated by 4 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $8.12, reflecting a 1.5% increase from the previous $8.00. Analysts' actions include both raises and lowers in ratings and price targets, indicating a dynamic perspective on the company's performance. Adtran Holdings faces challenges in market capitalization, revenue growth, net margin, ROE, and ROA, but maintains a sound debt management profile.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:01 pm

ZETA

Zeta Global Holdings (NYSE:ZETA) has received mixed analyst ratings over the last three months, with a recent shift towards more bullish views. The average 12-month price target for ZETA has increased to $13.2, up from $12.50. Analysts from Morgan Stanley, Barclays, and Needham have updated their ratings and price targets, reflecting optimism based on ZETA's performance and market position. ZETA's financials show strong revenue growth and efficient cost management but highlight challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:00 pm

NFLX

Netflix Inc (NASDAQ:NFLX) is expected to see a revenue and earnings growth boost in 2024 due to a planned price increase for subscribers, according to UBS analyst John Hodulik. Hodulik maintains a Buy rating on Netflix and has raised the price target from $570 to $685. The price increase, along with growth in Netflix's ad-supported tier, is anticipated to drive revenue growth to 15% in 2024, up from 7% in 2023. Netflix's strong pricing power and its share of U.S. TV viewing increasing to 7.9% in January 2024 are also highlighted as positive factors. Netflix aims to add 20 million net new subscribers in 2024, an increase from a previous estimate of 18 million.

Portfolio Pulse from Chris Katje

February 28, 2024 | 8:13 pm

ENFN

Goldman Sachs analyst Gabriela Borges downgraded Enfusion Inc (NYSE:ENFN) from Neutral to Sell, lowering the price target from $9 to $8. Despite underperforming the NASDAQ by 54% over the last 12 months, Borges expects ENFN to remain range-bound in 2024 due to a stable hedge fund market. She is conservative in her revenue growth estimates and notes that Enfusion's growth will need to come from company-specific improvements. Borges also highlights the challenges in converting existing funds and expects Customer Acquisition Cost (CAC) to remain high. Fiscal 2023 revenue and EPS projections were slightly adjusted.

Portfolio Pulse from Anusuya Lahiri

February 28, 2024 | 8:11 pm

APLS

In the past three months, 18 analysts have provided diverse ratings for Apellis Pharmaceuticals (NASDAQ:APLS), with a consensus 12-month price target of $75.94, marking a 12.6% increase from the previous target. The ratings range from bullish to bearish, reflecting varied perspectives on the company's performance and outlook. Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, has shown significant revenue growth and strong profitability despite challenges in market capitalization, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:01 pm

TBLA

Taboola.com (NASDAQ:TBLA) received mixed analyst ratings over the past three months, with a total of 4 bullish ratings. The average 12-month price target for TBLA has been raised to $5.75 from $5.00, indicating a 15.0% increase. Analysts from Needham and B. Riley Securities have raised their price targets to $6.00, reflecting optimism about the company's future performance. Despite positive revenue growth of 8.35% as of September 30, 2023, Taboola.com's financial indicators such as net margin, ROE, and ROA remain below industry averages, suggesting potential challenges ahead.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:01 pm

HSIC

Henry Schein (NASDAQ:HSIC) has been analyzed by 5 analysts, showing a mix of bullish to indifferent sentiments with no bearish views. The average 12-month price target for HSIC has increased to $83.8, up 8.13% from $77.50. Analysts from Evercore ISI Group, Barrington Research, Piper Sandler, Leerink Partners, and JP Morgan have raised their price targets, reflecting positive adjustments based on the company's performance and market conditions. Henry Schein's financial performance is strong, with a market capitalization above the industry average, a revenue growth rate of 3.1%, and high net margin and ROE compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:00 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has been rated by 5 analysts in the last three months, all maintaining an indifferent stance. The 12-month price targets show an average of $23.4, up 6.36% from the previous $22.00. The company's financial performance indicates a significant revenue growth of 2621.54% over 3 months, with a market capitalization above industry average, a net margin of -41.95%, an ROE of -4.05%, and an ROA of -3.57%. Its debt-to-equity ratio is low at 0.01.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:00 pm

GO

Analysts have diverse opinions on Grocery Outlet Holding (NASDAQ:GO), with recent evaluations showing a shift towards a more positive outlook. The average 12-month price target is now $30.2, down from $34.50. Analyst actions include adjustments to ratings and price targets, reflecting changes in market conditions and company performance. Grocery Outlet's financials indicate solid revenue growth, exceptional net margin, and strong ROE and ROA, with a debt-to-equity ratio below industry average.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 8:00 pm

LI

Li Auto reported that BYD plans to choose a location in Mexico for a new factory by the end of the year, aiming for a production capacity of 150,000 autos annually. Mexican officials have shown a positive response to BYD's intentions to sell in the Mexico market, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 7:45 pm